CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells, covering 2024-02-09 to 2024-02-09. Get the full timeline:
Most recent: Clinical Trial Update: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation [Phase 1]